Author

Chenglong Han 1

1 Janssen R&D, LLC,Spring House,United States

PATIENT-REPORTED OUTCOMES CAN BE USED TO MONITOR CONTINUOUS CLINICAL RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB: RESULTS FROM THE PURSUIT MAINTENANCE STUDY

Walter Reinisch, Jean-Frederic Colombel, Brian G. Feagan, Chenglong Han, Colleen W. Marano, Richard S Strauss, Peter R. Gibson, William Sandborn, Susan Huyck, Freddy Cornillie, Paul Rutgeerts

Ustekinumab Improved Work Productivity in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Induction and Maintenance Studies

Dominik Naessens, Chenglong Han, Hongyan Zhang, Jewel Johanns, Colleen W. Marano, Bruce E. Sands

USTEKINUMAB IMPROVES PRODUCTIVITY AND REDUCES WORK LIMITATION OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THREE PHASE 3 CLINICAL TRIALS

Bruce E. Sands, Chenglong Han, Dominik Naessens, Christopher Gasink, Douglas Jacobstein, L.L. Gao, Brian G. Feagan

Item 1 - 3 / 3
1